Periodontal disease in a patient receiving Bevacizumab: a case report

Dorothy M Gujral, Sanjeev Bhattacharyya, Peter Hargreaves, Gary W Middleton

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported before.
Original languageEnglish
Pages (from-to)47
JournalJournal of medical case reports
Publication statusPublished - 2008


Dive into the research topics of 'Periodontal disease in a patient receiving Bevacizumab: a case report'. Together they form a unique fingerprint.

Cite this